The New Frontiers in Multiple Sclerosis Treatment
Multiple sclerosis (MS) research is moving faster than ever. The last 18 months have brought new approvals and expanded access to existing drugs. Experimental therapies have emerged. Only a few years ago, these would have been considered science fiction. While not every treatment is a magic bullet, many are reshaping how neurologists think about managing—and possibly reversing—the disease.
A New Twist on an MS Workhorse
Ocrevus has long been a mainstay in MS treatment, but its newest form, Ocrevus Zunovo, is a game-changer for convenience. Approved by the FDA in September 2024, this isn’t the usual multi-hour IV drip. Instead, it’s a quick, twice-a-year 10-minute subcutaneous injection. That means less time in the clinic. It results in fewer scheduling headaches. The same proven effect against both relapsing and progressive forms of MS is maintained. For patients who dread infusion day, this is a welcome upgrade.
The Pill That Crosses Borders
In March 2025, the UK’s National Health Service made headlines. It became the first in Europe to roll out cladribine as an at-home oral therapy. This was specifically for patients with active relapsing-remitting MS. The drug isn’t new. Cladribine tablets have been available in some countries for years. However, this move dramatically expands who can get it. For many in the UK, this is the first time they can manage their MS treatment at home. They can do this from their own kitchen counter. They no longer need to visit a hospital. This is a significant change from receiving treatment in a hospital ward.
The BTK Inhibitor Race
The next big breakthrough might belong to a class of drugs known as BTK inhibitors. They are designed to fine-tune immune cell activity. They achieve this without broadly shutting the immune system down.
Tolebrutinib, developed by Sanofi, has been granted FDA Breakthrough Therapy designation. It is for non-relapsing secondary progressive MS. This is a form of the disease that currently has no approved treatments. In March 2025, the FDA accepted it for priority review, with a decision expected by September 28, 2025. Phase 3 trials showed it could significantly slow disability progression in progressive MS. However, it fell short of its goals for relapsing forms.
Then there’s fenebrutinib from Roche. It’s still in Phase 3 testing for both relapsing and progressive MS, with completion expected over the next few years. Early data has been impressive. Nearly every patient in one study stayed relapse-free for a year. However, concerns over liver safety mean researchers are moving carefully.
Rebuilding the Brain, Not Just Defending It
Most MS drugs aim to slow damage, but several experimental approaches are trying to repair the nervous system. These “remyelinating” therapies—including PIPE-307, PTD802, and FTX-101—are still early in development. The goal is to coax the brain into regenerating the protective myelin sheath around nerve fibers. If successful, these drugs could actually restore lost function rather than just preventing future loss.
Another bold idea: inverse vaccines. These use tiny nanoparticles to re-educate immune cells. They stop them from targeting the body’s own tissues, instead of training the immune system to attack a foreign invader. Early human trials are underway. Approval is still years away. Researchers are calling them a potential “holy grail” for autoimmune diseases.
Cell Therapies and the One-and-Done Dream
Meanwhile, the MS world is buzzing about cellular therapies like CAR-T, azer-cel, and g-NK therapy. These are being tested in progressive MS to “reset” the immune system entirely. In theory, one treatment could provide long-lasting, possibly permanent remission. These trials are still in Phase 1. The idea of a one-and-done MS therapy is enough to make patients and doctors take notice.
Other Drugs to Watch
Not every promising treatment fits neatly into a single category. Frexalimab is an experimental monoclonal antibody. It is being studied for relapsing MS. It works with a unique mechanism targeting CD40L, which is a key immune signaling pathway. Meanwhile, tegomil fumarate is a streamlined cousin of the widely used Tecfidera. It received a positive opinion from European regulators in May 2025. It was approved for use in patients as young as 13.
The Takeaway
For decades, MS treatment was about slowing an inevitable decline. Now, the field is full of therapies that aim to halt progression. These therapies also repair damage and make treatment itself less of a burden. Ocrevus Zunovo and expanded access to cladribine are already here, making life easier for patients. Tolebrutinib could arrive by the end of this year. It could potentially give new hope to those with progressive forms of the disease. And just over the horizon, remyelinating drugs, inverse vaccines, and cell-based therapies are promising new possibilities. The future of MS care is not just about control. It is about recovery.
If the next decade delivers just half of what’s in the pipeline, MS treatment could undergo radical changes. The landscape might change significantly. It might become more personalized and more effective. Perhaps, for the first time, it could even become curative.
If you want, I can create a “reader-friendly drug guide” version. Each treatment will have a short, punchy profile. This makes it easy to skim. That way you could post it online without it looking like a medical journal.